Orano Med

Orano Med is a clinical-stage biotechnology company with the ambition to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emmiter Therapy (TAT). The company develops several treatments using 212Pb combined with various targeting agents; it has formed multiple collaborations with prestigious institutions and biopharmaceutical companies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in France and in the US and is currently investing to further expand its GMP-manufacturing capacities for 212Pb radiolabeled pharmaceuticals in North America and Europe.